Clinical Report: Long-Term Data Boost MCO-010

Overview

Nanoscope Therapeutics will present four-year follow-up data from the MCO-010 optogenetic gene therapy program for retinitis pigmentosa at the 59th Annual Scientific Meeting of the Retina Society.

Background

Retinitis pigmentosa (RP) is a group of inherited retinal diseases leading to progressive vision loss. The development of innovative therapies, such as MCO-010, is crucial as they offer treatment options for patients with severe vision loss. MCO-010 represents a mutation-agnostic approach, making it accessible to a broader patient population without the need for genetic testing.

Data Highlights

Detailed four-year efficacy and safety results for MCO-010 will be presented at the Retina Society meeting. Previous data from the RESTORE Phase IIb/III trial indicated sustained vision improvements at three years.

Key Findings

• MCO-010 is designed as a one-time intravitreal gene therapy for retinal degeneration.
• Patients treated with MCO-010 showed maintained visual acuity gains four years after treatment.
• The therapy is mutation agnostic and does not require genetic testing prior to administration.
• MCO-010 has received multiple regulatory designations, including FDA Fast Track and Orphan Drug status.
• Phase II data have been generated for MCO-010 in Stargardt disease, with further studies planned.

Clinical Implications

The findings from the MCO-010 program may inform treatment strategies for patients with retinitis pigmentosa.

Conclusion

The presentation of four-year data on MCO-010 is expected to provide insights into the long-term efficacy and safety of this therapy for retinitis pigmentosa.

Related Resources & Content

1. Nanoscope Therapeutics, Nanoscope Therapeutics, 2026 -- Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting
2. Nanoscope Therapeutics, Nanoscope Therapeutics, 2026 -- Nanoscope Therapeutics Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for MOGENRY for the Treatment of Retinitis Pigmentosa with Severe Vision Loss
3. Ophthalmology Management, Ophthalmology Management, 2025 -- Nanoscope Study Reveals Durable 3 Year Vision Improvements of MCO010 in Retinitis Pigmentosa
4. Retinal Physician, Retinal Physician, 2025 -- Nanoscope Reports Sustained MCO-010 Safety
5. Clinical Research in Cardiology — Long-term Impact of Cardiac Contractility Modulation on Patients with Heart Failure Due to Left Ventricular Systolic Dysfunction
6. retinal physician — Nanoscope Reports Sustained MCO-010 Safety
7. ICER - Retinitis Pigmentosa
8. EURETINA IRD Consensus Supplement
9. C. Clinical Guidelines
10. RESTORE Phase 2b/3 Trial Data Show Lasting BCVA Improvement in RP Patients | Ophthalmology Management
11. ASRS 2026: MCO-010 optogenetic therapy sustains 3-line vision gains at 3 years in retinitis pigmentosa | Eye Care Network - Modern Retina
12. CO50 Analysis of Patient-Reported Outcomes of MCO-010 Mutation Agnostic Optogenetic Therapy for Retinitis Pigmentosa: 12-Month Results from a Phase 2b Randomized, Sham-Controlled, Patient- and Assessor-Masked Clinical Trial (RESTORE) - Value in Health
13. Nanoscope Therapeutics Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for MOGENRY for the Treatment of Retinitis Pigmentosa with Severe Vision Loss - Nanoscope Therapeutics
14. Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics
15. sham-controlled trial designed to generate robust evidence of the efficacy and safety of *sonpiretigene* for RP patients with severe vision loss.
16. Advantages of human opsins in optogenetic visual restoration - PMC
17. Gene therapy: GS030-DP AND Medical device: GS030-MD in Non-syndromic Retinitis Pigmentosa - Clinical Trials Registry - ICH GCP
18. Optogenetic therapy for retinal degenerative diseases: A review.
19. A Systematic Review of Optogenetic Vision Restoration: History, Challenges, and New Inventions from Bench to Bedside - PMC